Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics

Alpine Immune Sciences, Inc. (ALPN): $8.25

0.24 (+3.00%)

POWR Rating

Component Grades













Add ALPN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where ALPN ranks best; there it ranks ahead of 70.09% of US stocks.
  • ALPN's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • ALPN ranks lowest in Momentum; there it ranks in the 12th percentile.

ALPN Stock Summary

  • Of note is the ratio of Alpine Immune Sciences Inc's sales and general administrative expense to its total operating expenses; merely 7.65% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for Alpine Immune Sciences Inc comes in at 151.13%, a number that bests 94.78% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ALPN comes in at -35.57% -- higher than that of only 11.41% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Alpine Immune Sciences Inc are SYRS, ABUS, MGNX, IMGN, and CLLS.
  • ALPN's SEC filings can be seen here. And to visit Alpine Immune Sciences Inc's official web site, go to

ALPN Valuation Summary

  • ALPN's price/sales ratio is 12.7; this is 11.89% higher than that of the median Healthcare stock.
  • ALPN's price/sales ratio has moved NA NA over the prior 76 months.
  • Over the past 76 months, ALPN's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALPN.

Stock Date P/S P/B P/E EV/EBIT
ALPN 2021-08-31 12.7 5.2 -6.7 -7.0
ALPN 2021-08-30 12.3 5.1 -6.5 -6.8
ALPN 2021-08-27 12.7 5.2 -6.7 -7.0
ALPN 2021-08-26 12.3 5.1 -6.5 -6.8
ALPN 2021-08-25 12.6 5.2 -6.6 -6.9
ALPN 2021-08-24 12.3 5.0 -6.4 -6.7

ALPN Growth Metrics

    The year over year revenue growth rate now stands at 304.38%.
  • Its 4 year price growth rate is now at -83.06%.
  • Its 5 year cash and equivalents growth rate is now at 53.33%.
Over the past 33 months, ALPN's revenue has gone up $23,851,000.

The table below shows ALPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 24.556 -9.868 -41.508
2021-06-30 17.953 -45.394 -34.151
2021-03-31 11.448 23.807 -33.05
2020-12-31 9.335 30.084 -27.94
2020-09-30 4.576 33.762 -27.738
2020-06-30 2.952 28.579 -33.076

ALPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALPN has a Quality Grade of C, ranking ahead of 68.11% of graded US stocks.
  • ALPN's asset turnover comes in at 0.122 -- ranking 247th of 682 Pharmaceutical Products stocks.
  • SELB, TXMD, and QGEN are the stocks whose asset turnover ratios are most correlated with ALPN.

The table below shows ALPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.122 1 -0.458
2021-03-31 0.086 1 -0.661
2020-12-31 0.083 1 -0.777
2020-09-30 0.051 1 -1.140
2020-06-30 0.044 1 -0.895
2020-03-31 0.047 1 -0.716

ALPN Price Target

For more insight on analysts targets of ALPN, see our ALPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

ALPN Stock Price Chart Interactive Chart >

Price chart for ALPN

ALPN Price/Volume Stats

Current price $8.25 52-week high $14.40
Prev. close $8.01 52-week low $6.00
Day low $7.72 Volume 68,700
Day high $8.30 Avg. volume 112,640
50-day MA $8.56 Dividend yield N/A
200-day MA $9.99 Market Cap 250.21M

Alpine Immune Sciences, Inc. (ALPN) Company Bio

Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.

ALPN Latest News Stream

Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream

Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about Alpine Immune Sciences Inc that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythemat...

Benzinga | February 9, 2022

Alpine Immune Sciences (ALPN) Receives a Buy from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Alpine Immune Sciences (ALPN – Research Report), with a price target of $21.00. The company's shares closed last Thursday at $7.27, close to its 52-week low of $7.18. According to, Pantginis is ranked 0 out of 5 stars with an average return of -18.8% and a 23.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Alpine Immune Sciences is a Moderate Buy with an average price target of $21.00.

Brian Anderson on TipRanks | February 4, 2022

Leonard Rickey Investment Advisors P.L.L.C. ...

Investment company Leonard Rickey Investment Advisors P.L.L.C. (Current Portfolio) buys BTC iShares MSCI USA Min Vol Factor ETF, iShares TIPS Bond ETF, Vanguard Total International Stock, The Energy Select Sector SPDR Fund, Nike Inc, sells Vanguard Emerging Markets Government Bond ETF, Micron Technology Inc, eBay Inc, iShares MSCI All Country Asia ex Japan Index Fund, Alpine Immune Sciences Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Leon

Yahoo | February 1, 2022

Alpine Immune Sciences (ALPN) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 10, 2022

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo -6.25%
3-mo 10.29%
6-mo -32.65%
1-year -31.08%
3-year 44.23%
5-year -14.06%
YTD -40.43%
2021 9.92%
2020 228.13%
2019 4.35%
2018 -67.14%
2017 25.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.614 seconds.